EP4301859A1 - Enhanced Targeting Using Antibody-Oligonucleotide Conjugates
Summary
The European Patent Office has published patent application EP4301859A1 for Code Biotherapeutics, Inc. and University of Maryland, College Park, covering enhanced targeting technology using antibody-oligonucleotide conjugates. The patent application was published on April 8, 2026, with inventors Muro, Roki, and Getts. Designated states include all EU contracting states for potential validation.
What changed
The EPO published patent application EP4301859A1 covering enhanced targeting using antibody-oligonucleotide conjugates, assigned to Code Biotherapeutics, Inc. and University of Maryland, College Park. The application contains standard bibliographic data including inventors Muro, Roki, and Getts, with IPC classifications in C12N 15/115, C07K 17/02, and A61K 47/42.
Patent applicants and licensees should review the publication to confirm designation coverage aligns with their commercial interests across EU contracting states. The patent grant establishes exclusive IP rights in designated territories upon successful prosecution and validation.
Archived snapshot
Apr 19, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
Publication EP4301859A1 Kind: A1 Apr 08, 2026
Applicants
Code Biotherapeutics, Inc., University of Maryland, College Park
Inventors
MURO, Silvia, ROKI, Niksa, GETTS, Robert
IPC Classifications
C12N 15/115 20100101AFI20250423BHEP C07K 17/02 20060101ALI20250423BHEP A61K 47/42 20170101ALI20250423BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.